KDR and neoplasm: Anlotinib is a novel multitarget tyrosine kinase inhibitor that mainly inhibits vascular endothelial growth factor receptor 2 and 3 (VEGFR2/3), fibroblast growth factor 1–4 (FGFR1-4), platelet-derived growth factor receptor α and β (PDGFR α/β), C-Kit and Ret.11 VEGFR, FGFR and PDGFR are related to tumor angiogenesis and growth.